GGrantIndex
← Leaderboards

Carla Rothlin

Yale University

$8,894,958
Attributed
$17,295,339
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,295,339 · 7

By mechanism

R01$8,931,876 · 3
T32$2,999,322 · 1
R56$2,511,356 · 1
RF1$2,392,160 · 1
R21$460,625 · 1

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposMouse ModelGeneticAblationReceptor Protein-Tyrosine KinasesSignal TransductionImmuneResponseT-LymphocyteImmune ResponseMolecularMediatingCellsSignal PathwayBaseKnock-OutPathway InteractionsMertk GeneInflammatoryKnockout MiceInflammationResistanceInhibitor/AntagonistReporting

Grant awards (33)

Inflammation in MERTK-dependent retinitis pigmentosa$663,495
R01 · FY2025 · EY · contact PI
Interdisciplinary Immunology Training Program$216,204
T32 · FY2025 · AI
Inflammation in MERTK-dependent retinitis pigmentosa$663,495
R01 · FY2024 · EY · contact PI
Interdisciplinary Immunology Training Program$508,024
T32 · FY2024 · AI
Naïve T cell archetypes and anti-tumor immunity$209,375
R21 · FY2024 · AI · contact PI
Augmenting AXL and MERTK function to restrain cognitive decline and improve health span in mouse models of Alzheimer's Disease$2,392,160
RF1 · FY2023 · AG · contact PI
Inflammation in MERTK-dependent retinitis pigmentosa$679,733
R01 · FY2023 · EY · contact PI
Interdisciplinary Immunology Training Program$515,532
T32 · FY2023 · AI
Naïve T cell archetypes and anti-tumor immunity$251,250
R21 · FY2023 · AI · contact PI
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease$1,255,677
R56 · FY2022 · AG
Interdisciplinary Immunology Training Program$464,219
T32 · FY2022 · AI
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease$1,255,679
R56 · FY2021 · AG
Interdisciplinary Immunology Training Program$495,189
T32 · FY2021 · AI
An innate immune checkpoint in cancer immunotherapy$458,186
R01 · FY2021 · CA · contact PI
An innate immune checkpoint in cancer immunotherapy$415,512
R01 · FY2021 · CA · contact PI
An innate immune checkpoint in cancer immunotherapy$527,107
R01 · FY2020 · CA · contact PI
Interdisciplinary Immunology Training Program$350,163
T32 · FY2020 · AI
Interdisciplinary Immunology Training Program$449,991
T32 · FY2019 · AI
An innate immune checkpoint in cancer immunotherapy$444,441
R01 · FY2019 · CA · contact PI
An innate immune checkpoint in cancer immunotherapy$176,697
R01 · FY2019 · CA · contact PI
An innate immune checkpoint in cancer immunotherapy$468,186
R01 · FY2018 · CA · contact PI
TAM receptor tyrosine kinases in inflammatory boweldisease$416,250
R01 · FY2018 · AI · contact PI
An innate immune checkpoint in cancer immunotherapy.$113,240
R01 · FY2018 · CA · contact PI
TAM receptor tyrosine kinases in inflammatory boweldisease$487,260
R01 · FY2017 · AI · contact PI
An innate immune checkpoint in cancer immunotherapy$455,406
R01 · FY2017 · CA · contact PI
TAM receptor tyrosine kinases in inflammatory boweldisease$510,052
R01 · FY2016 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory bowel disease$23,622
R01 · FY2016 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory boweldisease$416,250
R01 · FY2015 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory boweldisease$416,250
R01 · FY2014 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory bowel disease$376,805
R01 · FY2013 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory bowel disease$400,302
R01 · FY2012 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory bowel disease$399,584
R01 · FY2011 · AI · contact PI
TAM receptor tyrosine kinases in inflammatory bowel disease$420,003
R01 · FY2010 · AI · contact PI